Viyash Scientific cash flow

Latest FY26

Cash from operations: ₹323cr+287.4% on FY25
Capital spending: ₹135cr+244.6% on FY25
Free cash flow: ₹188cr+325.1% on FY25
Cash from financing: −₹123cr−₹60.7 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	234	66.5	61.5	55.7
	—	69.2	60.8	48.1	35.5
	—	−9.3	−2.7	−0.7	−1.2
	—	0.0	0.0	0.0	−0.0
	—	0.0	0.0	−0.0	11.4
	—	36.3	32.4	0.0	35.4
	—	−6.6	8.1	15.4	0.0
	—	50.6	−9.9	31.6	84.8
	—	−9.5	0.0	−11.0	0.0
	—	0.0	0.0	0.0	−1.0
	—	−104	−46.9	0.3	5.1
	—	−284	−47.9	−8.8	−41.3
	—	0.0	−0.0	−0.0	0.0
	—	−0.1	0.0	0.0	1.6
	—	58.9	6.4	−37.1	−17.0
Cash from operating activities
	338	349	44.3	−54.6	−138
	—	35.2	66.7	99.3	169
	—	384	111	44.7	31.5
	—	61.3	27.6	14.1	14.6
	—	323	83.4	30.6	16.8
Cash from investing activities
	—	135	39.1	30.8	86.2
	—	36.9	9.7	19.2	11.7
	—	0.0	0.0	5.7	0.0
	—	2.9	0.0	0.0	0.0
	—	0.0	0.0	0.0	0.0
	—	9.8	2.5	0.6	1.2
	—	1.1	2.2	10.9	8.3
	—	−84.1	−24.8	−5.9	−65.0
Cash from financing activities
	—	39.5	0.0	0.0	0.0
	—	92.5	0.0	0.0	0.0
	—	39.9	0.0	0.0	0.0
	—	5.2	268	113	113
	—	213	271	58.5	35.6
	—	13.6	12.5	0.0	9.6
	—	—	—	10.8	0.0
	—	69.0	51.3	45.3	35.6
	—	4.9	1.9	0.0	0.0
	—	0.0	7.5	−0.1	−0.3
	—	−123	−60.7	−1.4	32.2
	—	115	−2.2	23.2	−15.9
	—	115	−2.2	23.2	−15.9
	—	—	—	64.8	41.6
Reference items
	594	653	162	61.4	12.0
	18.9%	19.1%	10.4%	4.5%	0.8%
	188	188	44.3	−0.2	−69.4
	—	109	−11.9	7.8	—
	₹4.31	₹4.31	₹1.01	−₹0.00	−₹1.59
	47.48×	—	—	—	—
	—	1.44×	2.58×	−1.03×	−0.14×
	—	61.3	27.6	14.1	14.6
	—	69.0	51.3	45.3	35.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VIYASH₹204.52

Viyash Scientific Ltd.

· Pharma & Health

₹ CrorePeersAARTIDRUGS YATHARTH THYROCARE SUPRIYA STAR SPARC SHILPAMED RUBICONMcap ₹8,934 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	55.7	61.5	66.5	233.6	—
+ Finance Costs	35.5	48.1	60.8	69.2	—
+ Interest Income	-1.2	-0.7	-2.7	-9.3	—
+ Dividend Income	-0.0	0.0	0.0	0.0	—
+ Fair Value (Gains) / Losses	11.4	-0.0	0.0	0.0	—
+ Share-based Payments	35.4	0.0	32.4	36.3	—
+ Unrealised FX (Gain) / Loss	0.0	15.4	8.1	-6.6	—
+ Other Non-cash Items	84.8	31.6	-9.9	50.6	—
+ Other — Cash Effects are Investing / Financing	0.0	-11.0	0.0	-9.5	—
+ Other Reconciling Items	-1.0	0.0	0.0	0.0	—
Changes in Working Capital
+ Inventories	5.1	0.3	-46.9	-103.9	—
+ Trade Receivables — Current	-41.3	-8.8	-47.9	-284.1	—
+ Other Current Assets	0.0	-0.0	-0.0	0.0	—
+ Other Bank Balances	1.6	0.0	0.0	-0.1	—
+ Trade Payables — Current	-17.0	-37.1	6.4	58.9	—
Cash from Operating Activities
Profit Before Tax (per I/S)	-137.7	-54.6	44.3	349.0	337.9
+ Total Adjustments (incl. Working Capital)	169.1	99.3	66.7	35.2	—
Cash from Operations (pre-tax)	31.5	44.7	111.0	384.2	—
+ Income Taxes Paid	14.6	14.1	27.6	61.3	—
Cash from Operating Activities	16.8	30.6	83.4	322.9	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	86.2	30.8	39.1	134.7	—
+ Disp of Fixed Assets	11.7	19.2	9.7	36.9	—
+ Acq of Other Long-term Assets	0.0	5.7	0.0	0.0	—
+ Disp of Other Long-term Assets	0.0	0.0	0.0	2.9	—
+ Dividends Received — Investing	0.0	0.0	0.0	0.0	—
+ Interest Received — Investing	1.2	0.6	2.5	9.8	—
+ Other Inflows / (Outflows) — Investing	8.3	10.9	2.2	1.1	—
Cash from Investing Activities	-65.0	-5.9	-24.8	-84.1	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	0.0	39.5	—
+ Proceeds from Other Equity Instruments	0.0	0.0	0.0	92.5	—
+ Proceeds from Exercise of Stock Options	0.0	0.0	0.0	39.9	—
+ Proceeds from Borrowings	113.3	113.3	268.2	5.2	—
+ Repayment of Borrowings	35.6	58.5	270.8	212.9	—
+ Payment of Lease Liabilities	9.6	0.0	12.5	13.6	—
+ Payment of Finance Lease Liabilities	0.0	10.8	—	—	—
+ Interest Paid	35.6	45.3	51.3	69.0	—
+ Dividends Paid	0.0	0.0	1.9	4.9	—
+ Other Inflows / (Outflows) — Financing	-0.3	-0.1	7.5	0.0	—
Cash from Financing Activities	32.2	-1.4	-60.7	-123.3	—
Net Changes in Cash (pre-FX)	-15.9	23.2	-2.2	115.5	—
Net Changes in Cash	-15.9	23.2	-2.2	115.5	—
Closing Cash	41.6	64.8	—	—	—
Reference Items
EBITDA	12.0	61.4	161.8	652.5	593.9
EBITDA Margin %	0.84	4.48	10.43	19.08	18.86
Free Cash Flow (CFO − Capex)	-69.4	-0.2	44.3	188.2	188.2
Free Cash Flow to Equity	—	7.8	-11.9	108.6	—
Free Cash Flow per Basic Share	-1.59	-0.00	1.01	4.31	4.31
Price to Free Cash Flow	—	—	—	—	47.48
Cash Flow to Net Income	-0.14	-1.03	2.58	1.44	—
Cash Paid for Taxes	14.6	14.1	27.6	61.3	—
Cash Paid for Interest	35.6	45.3	51.3	69.0	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.